

Date: 3<sup>rd</sup> March 2026  
Ref: CORP 25/26 - 257

Dear xxx

**Freedom of Information request: Treatment of Mantle Cell Lymphoma (MCL) (CORP 25/26 – 257)**

Thank you for your request for information which the Trust received on 9<sup>th</sup> February 2026.

Your Request:

- 1) *How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?*
- 2) *How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:*
  - *BR (Bendamustine + rituximab)*
  - *VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)*
  - *R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)*
  - *R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)*
  - *CVP (cyclophosphamide, vincristine and prednisolone)*
  - *Brukinsa (zanubrutinib)*
  - *Imbruvica (ibrutinib)*
  - *Velcade (bortezomib) + chemotherapy*
  - *Tecartus (brexucabtegene autoleucel)*
  - *R-BAC (rituximab, bendamustine and cytarabine)*
  - *R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)*
  - *Any other systemic anti-cancer therapy*
  - *Wait and watch (monitoring only, no active treatment)*
- 3) *How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:*

*For this question, please only count patients that have received the below treatments for the first time.*

  - *BR (Bendamustine + rituximab)*
  - *VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)*
  - *R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)*
  - *R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)*
  - *CVP (cyclophosphamide, vincristine and prednisolone)*

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



- *Brukina (zanubrutinib)*
  - *Imbruvica (ibrutinib)*
  - *Velcade (bortezomib) + chemotherapy*
  - *Tecartus (CAR-T)*
  - *R-BAC (rituximab, bendamustine and cytarabine)*
  - *R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)*
  - *Any other systemic anti-cancer therapy*
  - *Wait and watch (monitoring only, no active treatment)*
- 4) *If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.*


Please find the Trust's response below:

- 1) **How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?**

There have been 6 patients treated for MCL in the last 12 months.

- 2) **How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:**
- **BR (Bendamustine + rituximab) - 0**
  - **VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) - 0**
  - **R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) - 0**
  - **R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) - 0**
  - **CVP (cyclophosphamide, vincristine and prednisolone) - 0**
  - **Brukina (zanubrutinib) - 0**
  - **Imbruvica (ibrutinib) - 0**
  - **Velcade (bortezomib) + chemotherapy - 0**
  - **Tecartus (brexucabtegene autoleucl) - 0**
  - **R-BAC (rituximab, bendamustine and cytarabine) - 0**
  - **R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) - 0**
  - **Any other systemic anti-cancer therapy - 0**
  - **Wait and watch (monitoring only, no active treatment) – not recorded**

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



**3) How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:**

**For this question, please only count patients that have received the below treatments for the first time.**

- **BR (Bendamustine + rituximab) - 0**
- **VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) - 0**
- **R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) - 0**
- **R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) - 0**
- **CVP (cyclophosphamide, vincristine and prednisolone) - 0**
- **Brukina (zanubrutinib) - 0**
- **Imbruvica (ibrutinib) - 0**
- **Velcade (bortezomib) + chemotherapy - 0**
- **Tecartus (CAR-T) - 0**
- **R-BAC (rituximab, bendamustine and cytarabine) - 0**
- **R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) - 0**
- **Any other systemic anti-cancer therapy - 0**
- **Wait and watch (monitoring only, no active treatment) – not recorded**

**4) If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.**


The Trust is not participating in any ongoing trials for MCL.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk)  
Head of Information Governance  
Velindre University NHS Trust  
2, Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales  
2nd Floor,  
Churchill House,  
Churchill Way,  
Cardiff,  
CF10 2HH  
Telephone: 0330 414 6421  
email: [wales@ico.org.uk](mailto:wales@ico.org.uk)

Yours sincerely

**Non Gwilym**  
**Interim Director of Corporate Governance**  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

